152 related articles for article (PubMed ID: 8384365)
1. Preparation of heptakis(2,6-di-O-ethyl)-beta-cyclodextrin and its nuclear magnetic resonance spectroscopic characterization.
Hirayama F; Kurihara M; Horiuchi Y; Utsuki T; Uekama K; Yamasaki M
Pharm Res; 1993 Feb; 10(2):208-13. PubMed ID: 8384365
[TBL] [Abstract][Full Text] [Related]
2. Heptakis(2,6-di-O-methyl-3-O-acetyl)-beta-cyclodextrin: A water-soluble cyclodextrin derivative with low hemolytic activity.
Hirayama F; Mieda S; Miyamoto Y; Arima H; Uekama K
J Pharm Sci; 1999 Oct; 88(10):970-5. PubMed ID: 10514341
[TBL] [Abstract][Full Text] [Related]
3. Inclusion complex of 3,9-bis(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c]quinoline-6-one (KCA-098) with heptakis(2,6-di-O-methyl)-beta-cyclodextrin: interaction and dissolution properties.
Yamada T; Imai T; Ouchi K; Otagiri M; Hirayama F; Uekama K
Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1264-9. PubMed ID: 10993223
[TBL] [Abstract][Full Text] [Related]
4. Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha- and -beta-cyclodextrins in aqueous solution.
Miyake K; Hirayama F; Uekama K
J Pharm Sci; 1999 Jan; 88(1):39-45. PubMed ID: 9874700
[TBL] [Abstract][Full Text] [Related]
5. Solid-state 13C nuclear magnetic resonance spectroscopic study on amorphous solid complexes of tolbutamide with 2-hydroxypropyl-alpha- and -beta-cyclodextrins.
Kimura K; Hirayama F; Arima H; Uekama K
Pharm Res; 1999 Nov; 16(11):1729-34. PubMed ID: 10571279
[TBL] [Abstract][Full Text] [Related]
6. Study of the interaction of clobazam with cyclodextrins in solution and in the solid state.
Nakai Y; el-Said Aboutaleb A; Yamamoto K; Saleh SI; Ahmed MO
Chem Pharm Bull (Tokyo); 1990 Mar; 38(3):728-32. PubMed ID: 2347015
[TBL] [Abstract][Full Text] [Related]
7. Chiral discrimination of phenethylamines with beta-cyclodextrin and heptakis(2,3-di-O-acetyl)beta-cyclodextrin by capillary electrophoresis and NMR spectroscopy.
Branch SK; Holzgrabe U; Jefferies TM; Mallwitz H; Matchett MW
J Pharm Biomed Anal; 1994 Dec; 12(12):1507-17. PubMed ID: 7696375
[TBL] [Abstract][Full Text] [Related]
8. Cyclodextrins as carriers for kavalactones in aqueous media: spectroscopic characterization of (S)-7,8-dihydrokavain and beta-cyclodextrin inclusion complex.
Pescitelli G; Bilia AR; Bergonzi MC; Vincieri FF; Di Bari L
J Pharm Biomed Anal; 2010 Aug; 52(4):479-83. PubMed ID: 20185265
[TBL] [Abstract][Full Text] [Related]
9. Comparative study on inclusion complexation of maltosyl-beta-cyclodextrin, heptakis(2,6-di-O-methyl)-beta-cyclodextrin and beta-cyclodextrin with fucosterol in aqueous and solid state.
Acartürk F; Imai T; Saito H; Ishikawa M; Otagiri M
J Pharm Pharmacol; 1993 Dec; 45(12):1028-32. PubMed ID: 7908969
[TBL] [Abstract][Full Text] [Related]
10. Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-beta-cyclodextrin, not 2,6-di-O-methyl-alpha-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells.
Motoyama K; Kameyama K; Onodera R; Araki N; Hirayama F; Uekama K; Arima H
Eur J Pharm Sci; 2009 Oct; 38(3):249-61. PubMed ID: 19664706
[TBL] [Abstract][Full Text] [Related]
11. [Development and pharmaceutical evaluation of hydrophobic cyclodextrin derivatives as modified-release drug carriers].
Hirayama F
Yakugaku Zasshi; 1993 Jun; 113(6):425-37. PubMed ID: 8355145
[TBL] [Abstract][Full Text] [Related]
12. Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue.
Uekama K; Hieda Y; Hirayama F; Arima H; Sudoh M; Yagi A; Terashima H
Pharm Res; 2001 Nov; 18(11):1578-85. PubMed ID: 11758766
[TBL] [Abstract][Full Text] [Related]
13. NMR spectroscopic investigation of inclusion complexes between cyclodextrins and the neurotoxin tetramethylenedisulfotetramine.
Mayer BP; Albo RL; Hok S; Valdez CA
Magn Reson Chem; 2012 Mar; 50(3):229-35. PubMed ID: 22383439
[TBL] [Abstract][Full Text] [Related]
14. Possible enhancing mechanism of the cutaneous permeation of 4-biphenylylacetic acid by beta-cyclodextrin derivatives in hydrophilic ointment.
Arima H; Miyaji T; Irie T; Hirayama F; Uekama K
Chem Pharm Bull (Tokyo); 1996 Mar; 44(3):582-6. PubMed ID: 8882455
[TBL] [Abstract][Full Text] [Related]
15. Interaction of heptakis (2,3,6-tri-O-methyl)-beta-cyclodextrin with cholesterol in aqueous solution.
Nishijo J; Moriyama S; Shiota S; Kamigauchi M; Sugiura M
Chem Pharm Bull (Tokyo); 2004 Dec; 52(12):1405-10. PubMed ID: 15577234
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats.
Arima H; Yunomae K; Miyake K; Irie T; Hirayama F; Uekama K
J Pharm Sci; 2001 Jun; 90(6):690-701. PubMed ID: 11357172
[TBL] [Abstract][Full Text] [Related]
17. Enhanced rectal absorption and reduced local irritation of the anti-inflammatory drug ethyl 4-biphenylylacetate in rats by complexation with water-soluble beta-cyclodextrin derivatives and formulation as oleaginous suppository.
Arima H; Kondo T; Irie T; Uekama K
J Pharm Sci; 1992 Nov; 81(11):1119-25. PubMed ID: 1447717
[TBL] [Abstract][Full Text] [Related]
18. Comparative enantioseparation of ketoprofen with trimethylated α-, β-, and γ-cyclodextrins in capillary electrophoresis and study of related selector-selectand interactions using nuclear magnetic resonance spectroscopy.
Samakashvili S; Salgado A; Scriba GK; Chankvetadze B
Chirality; 2013 Feb; 25(2):79-88. PubMed ID: 23255364
[TBL] [Abstract][Full Text] [Related]
19. Prominent inclusion effect of dimethyl-beta-cyclodextrin on photoisomerization of the thromboxane synthetase inhibitor (E)-4-(1-imidazoylmethyl)cinnamic acid.
Hirayama F; Utsuki T; Uekama K; Yamasaki M; Harata K
J Pharm Sci; 1992 Aug; 81(8):817-22. PubMed ID: 1403730
[TBL] [Abstract][Full Text] [Related]
20. NMR study of solid C60(gamma-cyclodextrin)2.
Tseng WY; Chen YH; Khairullin II; Cheng S; Hwang LP
Solid State Nucl Magn Reson; 1997 Aug; 8(4):219-29. PubMed ID: 9373902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
